Rocket Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Rocket Pharmaceuticals

10/08/2023 13:53

* Rocket Pharmaceuticals Inc  RCKT.OQ  reported a quarterly
adjusted loss of 82 cents​​ per share for the quarter ended in
June. The mean expectation of twelve analysts for the quarter
was for a loss of 79 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Rocket Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 82 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Rocket Pharmaceuticals Inc shares had fallen by 14.6% this
quarter and lost 13.3% so far this year.
    * The company reported a quarterly loss of $65.7 million.
    * Wall Street's median 12-month price target for Rocket
Pharmaceuticals Inc is $49.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 10 at 12:53 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.79          -0.82          Missed
 Mar. 31 2023      -0.85          -0.73          Beat
 Dec. 31 2022      -0.80          -0.92          Missed
 Sep. 30 2022      -0.79          -0.87          Missed